Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 11/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.97 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.97 |
| ▸ | SCN1A | P35498 | 2/20 | 0.69 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.69 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylbenactyzium SCHEMBL8816404 | 0.99 | CHRM1 (0.94) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Methylbenactyzium SCHEMBL60901 | 0.99 | CHRM1 (1.00) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Methylbenactyzium SCHEMBL8446490 | 0.96 | CHRM1 (0.95) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Lachesine SCHEMBL1946024 | 0.87 | CHRM1 (0.75) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Oxitefonium SCHEMBL29388802 | 0.86 | CHRM1 (0.73) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Metocinium SCHEMBL2108327 | 0.86 | CHRM2 (0.74) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Lachesine SCHEMBL3638169 | 0.86 | CHRM1 (0.73) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Oxitefonium SCHEMBL2733669 | 0.85 | CHRM1 (0.76) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Metocinium SCHEMBL2732726 | 0.85 | CHRM2 (0.72) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| SCHEMBL5158545 | 0.81 | MEN1 (0.68) | CHRM1CHRM2CHRM3CHRM4SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2585010-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH OVERACTIVE BLADDER | Mahashabde, Anu (US) | 2013-05-01 | — | — | EP | claimed |
| EP-2585011-A2 | INTRAVAGINAL DEVICES COMPRISING ANTICHOLINERGIC AGENTS, AND METHODS OF MAKING THEREOF | Mahashabde, Anu (US) | 2013-05-01 | — | — | EP | claimed |
| US-20120107385-A1 | METHOD OF TREATING CONDITIONS ASSOCIATED WITH OVERACTIVE BLADDER | TEVA WOMEN'S HEALTH, INC. | 2012-05-03 | — | — | US | claimed |
| US-20120053534-A1 | INTRAVAGINAL DEVICES COMPRISING ANTICHOLINERGIC AGENTS, AND METHODS OF MAKING THEREOF | TEVA WOMEN'S HEALTH, INC. | 2012-03-01 | — | — | US | claimed |
| WO-2011163358-A2 | INTRAVAGINAL DEVICES COMPRISING ANTICHOLINERGIC AGENTS, AND METHODS OF MAKING THEREOF | MAHASHABDE ANU (US) | 2011-12-29 | — | — | WO | claimed |
| WO-2011163356-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH OVERACTIVE BLADDER | MAHASHABDE ANU (US) | 2011-12-29 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1364659-B1 | REMEDIES FOR URINARY DISEASES COMPRISING LPA RECEPTOR CONTROLLING AGENTS | ONO PHARMACEUTICAL CO (JP) | 2009-11-11 | — | — | EP | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20260102381-A1 | Muscarinic Agent Combinations | Syremis Therapeutics, Ltd. (IL) | 2026-04-16 | — | — | US | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2024155775-A2 | COMPOSITIONS AND TECHNIQUES FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AND ENDOMETRIOSIS | DARE BIOSCIENCE, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20060069098-A1 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-03-30 | — | — | US | disclosed |
| US-20040039036-A1 | Water-soluble liquid internal medicine | ASTELLAS PHARMA INC. (JP) | 2004-02-26 | — | — | US | disclosed |
| CN-1476327-A | Water-soluble liquid internal medicine | ֮����ҩ��ʽ���� | 2004-02-18 | — | — | CN | disclosed |
| EP-1336408-A1 | WATER-SOLUBLE LIQUID INTERNAL MEDICINE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107385-A1 | METHOD OF TREATING CONDITIONS ASSOCIATED WITH OVERACTIVE BLADDER | ACHE, MMP1, CHRM3 | CHRM1 19/4885CHRM2 5/4885CHRM3 3/4885 |
| US-20040039036-A1 | Water-soluble liquid internal medicine | SLC10A2, SI, EDNRA | CHRM1 543/4885CHRM2 629/4885CHRM3 656/4885 |
| US-20260102381-A1 | Muscarinic Agent Combinations | CHRM1, CHRM4, CHRM2 | CHRM1 1/4885CHRM2 3/4885CHRM3 4/4885 |
| US-20060069098-A1 | Bicyclic compound | CRH, NR3C2, CRHR1 | CHRM1 115/4885CHRM2 308/4885CHRM3 1001/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | CHRM1 1604/4885CHRM2 880/4885CHRM3 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.